A detailed history of Values First Advisors, Inc. transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Values First Advisors, Inc. holds 197,516 shares of BLRX stock, worth $45,428. This represents 0.06% of its overall portfolio holdings.

Number of Shares
197,516
Previous 203,759 3.06%
Holding current value
$45,428
Previous $116,000 8.62%
% of portfolio
0.06%
Previous 0.07%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

SELL
$0.53 - $0.87 $3,308 - $5,431
-6,243 Reduced 3.06%
197,516 $106,000
Q2 2024

Jul 19, 2024

BUY
$0.56 - $0.86 $70 - $108
126 Added 0.06%
203,759 $116,000
Q1 2024

Apr 23, 2024

BUY
$1.03 - $1.56 $156,008 - $236,285
151,465 Added 290.34%
203,633 $228,000
Q4 2023

Jan 18, 2024

BUY
$1.31 - $1.86 $5,004 - $7,105
3,820 Added 7.9%
52,168 $81,000
Q3 2023

Nov 08, 2023

BUY
$1.23 - $2.45 $59,468 - $118,452
48,348 New
48,348 $87,000

Others Institutions Holding BLRX

About BioLineRx Ltd.


  • Ticker BLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,524,500
  • Market Cap $14.2M
  • Description
  • BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...
More about BLRX
Track This Portfolio

Track Values First Advisors, Inc. Portfolio

Follow Values First Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Values First Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Values First Advisors, Inc. with notifications on news.